Literature DB >> 12643150

Association of albuminuria and the metabolic syndrome.

Kevin Rowley1, Kerin O'Dea, James D Best.   

Abstract

Microalbuminuria clusters with the metabolic syndrome, and both conditions predict cardiovascular disease mortality. The reported relationships of microalbuminuria with the individual components of the metabolic syndrome (i.e., hyperglycemia, insulin resistance, hypertension, dyslipidemia, abdominal obesity) are variable. Each of these components, as well as intrauterine effects and diet and other lifestyle factors, may contribute to elevated risk of microalbuminuria in certain population groups. Recent evidence indicates a role for oxidation and inflammation in cardiovascular disease, and endothelial dysfunction (exacerbated by factors such as dyslipidemia) may be the mediator of this relationship. Because endothelial dysfunction can also be manifested as microalbuminuria, this provides a potential explanation of the observed association of the metabolic syndrome, chronic inflammation, and microalbuminuria.

Entities:  

Mesh:

Year:  2003        PMID: 12643150     DOI: 10.1007/s11892-003-0058-1

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  50 in total

1.  Microalbuminuria in hypertension is not a determinant of insulin resistance.

Authors:  Ingrid Toft; Kaare H Bønaa; Jorunn Eikrem; Ase Lund Bendiksen; Hege Iversen; Trond Jenssen
Journal:  Kidney Int       Date:  2002-04       Impact factor: 10.612

2.  Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.

Authors:  H C Gerstein; J F Mann; Q Yi; B Zinman; S F Dinneen; B Hoogwerf; J P Hallé; J Young; A Rashkow; C Joyce; S Nawaz; S Yusuf
Journal:  JAMA       Date:  2001-07-25       Impact factor: 56.272

3.  Cardiovascular morbidity and mortality associated with the metabolic syndrome.

Authors:  B Isomaa; P Almgren; T Tuomi; B Forsén; K Lahti; M Nissén; M R Taskinen; L Groop
Journal:  Diabetes Care       Date:  2001-04       Impact factor: 19.112

Review 4.  Lipids and the kidney.

Authors:  W F Keane
Journal:  Kidney Int       Date:  1994-09       Impact factor: 10.612

5.  Prevalence and risk factors of microalbuminuria in a cohort of African-American women with gestational diabetes.

Authors:  R C Go; R Desmond; J M Roseman; D S Bell; C Vanichanan; R T Acton
Journal:  Diabetes Care       Date:  2001-10       Impact factor: 19.112

6.  Risk factors for kidney damage in the adult population of Wadena, Minnesota. A prospective study.

Authors:  F C Goetz; D R Jacobs; B Chavers; J Roel; M Yelle; J M Sprafka
Journal:  Am J Epidemiol       Date:  1997-01-15       Impact factor: 4.897

7.  Urinary findings and renal function in adult Navajo Indians and associations with type 2 diabetes.

Authors:  W Hoy; S Jim; W Warrington; A Light; D Megill
Journal:  Am J Kidney Dis       Date:  1996-09       Impact factor: 8.860

8.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.

Authors:  K G Alberti; P Z Zimmet
Journal:  Diabet Med       Date:  1998-07       Impact factor: 4.359

9.  The multidimensional nature of renal disease: rates and associations of albuminuria in an Australian Aboriginal community.

Authors:  W E Hoy; J D Mathews; D A McCredie; D J Pugsley; B G Hayhurst; M Rees; E Kile; K A Walker; Z Wang
Journal:  Kidney Int       Date:  1998-10       Impact factor: 10.612

10.  Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes.

Authors:  P J Beisswenger; Z Makita; T J Curphey; L L Moore; S Jean; T Brinck-Johnsen; R Bucala; H Vlassara
Journal:  Diabetes       Date:  1995-07       Impact factor: 9.461

View more
  8 in total

Review 1.  Intracranial atherosclerotic stroke: specific focus on the metabolic syndrome and inflammation.

Authors:  Oh Young Bang
Journal:  Curr Atheroscler Rep       Date:  2006-07       Impact factor: 5.113

2.  Lung function and impaired kidney function in relation to metabolic syndrome.

Authors:  Kayoung Lee
Journal:  Int Urol Nephrol       Date:  2017-03-15       Impact factor: 2.370

3.  Blood pressure, atherosclerosis, and albuminuria in 10,113 participants in the atherosclerosis risk in communities study.

Authors:  Charles C Hsu; Frederick L Brancati; Brad C Astor; Wen Hong Kao; Michael W Steffes; Aaron R Folsom; Josef Coresh
Journal:  J Hypertens       Date:  2009-02       Impact factor: 4.844

4.  Clinical outcomes associated with albuminuria in central Australia: a cohort study.

Authors:  Rebecca Ritte; Joanne Luke; Craig Nelson; Alex Brown; Kerin O'Dea; Alicia Jenkins; James D Best; Robyn McDermott; Mark Daniel; Kevin Rowley
Journal:  BMC Nephrol       Date:  2016-08-05       Impact factor: 2.388

5.  Differential impacts of adiponectin on low-grade albuminuria between obese and nonobese persons without diabetes.

Authors:  Yuichiro Yano; Satoshi Hoshide; Joji Ishikawa; Toru Hashimoto; Kazuo Eguchi; Kazuyuki Shimada; Kazuomi Kario
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-10       Impact factor: 3.738

6.  Microalbuminuria in patients with chronic kidney disease at Parirenyatwa Hospital in Zimbabwe.

Authors:  Nyasha Chin'ombe; Ophius Msengezi; Hilda Matarira
Journal:  Pan Afr Med J       Date:  2013-01-28

7.  Long term metabolic syndrome induced by a high fat high fructose diet leads to minimal renal injury in C57BL/6 mice.

Authors:  Romain Dissard; Julie Klein; Cécile Caubet; Benjamin Breuil; Justyna Siwy; Janosch Hoffman; Laurent Sicard; Laure Ducassé; Simon Rascalou; Bruno Payre; Marie Buléon; William Mullen; Harald Mischak; Ivan Tack; Jean-Loup Bascands; Bénédicte Buffin-Meyer; Joost P Schanstra
Journal:  PLoS One       Date:  2013-10-03       Impact factor: 3.240

8.  Association of Microalbuminuria with Metabolic Syndrome among Aged Population.

Authors:  Xiao-Hong Li; Hai-Yan Lin; Shu-Hua Wang; Li-Ying Guan; Yi-Bing Wang
Journal:  Biomed Res Int       Date:  2016-04-21       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.